168 related articles for article (PubMed ID: 12477051)
1. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen.
Scott GK; Marden C; Xu F; Kirk L; Benz CC
Mol Cancer Ther; 2002 Apr; 1(6):385-92. PubMed ID: 12477051
[TBL] [Abstract][Full Text] [Related]
2. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
[TBL] [Abstract][Full Text] [Related]
3. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.
Scott GK; Marx C; Berger CE; Saunders LR; Verdin E; Schäfer S; Jung M; Benz CC
Mol Cancer Res; 2008 Jul; 6(7):1250-8. PubMed ID: 18644987
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region.
Han S; Lu J; Zhang Y; Cheng C; Li L; Han L; Huang B
Immunol Lett; 2007 Feb; 108(2):143-50. PubMed ID: 17270283
[TBL] [Abstract][Full Text] [Related]
5. Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Li G; Xie Q; Yang Z; Wang L; Zhang X; Zuo B; Zhang S; Yang A; Jia L
Int J Cancer; 2019 Dec; 145(12):3285-3298. PubMed ID: 31111958
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation.
Mulholland NM; Soeth E; Smith CL
Oncogene; 2003 Jul; 22(31):4807-18. PubMed ID: 12894222
[TBL] [Abstract][Full Text] [Related]
7. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-beta1 induced murine tissue inhibitor of metalloproteinases-1 gene expression.
Young DA; Billingham O; Sampieri CL; Edwards DR; Clark IM
FEBS J; 2005 Apr; 272(8):1912-26. PubMed ID: 15819885
[TBL] [Abstract][Full Text] [Related]
10. Promoter specific sensitivity to inhibition of histone deacetylases: implications for hormonal gene control, cellular differentiation and cancer.
Dressel U; Renkawitz R; Baniahmad A
Anticancer Res; 2000; 20(2A):1017-22. PubMed ID: 10810390
[TBL] [Abstract][Full Text] [Related]
11. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.
Contreras-Leal E; Hernández-Oliveras A; Flores-Peredo L; Zarain-Herzberg Á; Santiago-García J
Mol Carcinog; 2016 Oct; 55(10):1477-85. PubMed ID: 26331238
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
Li H; Wu X
Biochem Biophys Res Commun; 2004 Nov; 324(2):860-7. PubMed ID: 15474507
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
15. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
Hernandez M; Shao Q; Yang XJ; Luh SP; Kandouz M; Batist G; Laird DW; Alaoui-Jamali MA
Prostate; 2006 Aug; 66(11):1151-61. PubMed ID: 16652385
[TBL] [Abstract][Full Text] [Related]
16. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
Feng W; Lu Z; Luo RZ; Zhang X; Seto E; Liao WS; Yu Y
Int J Cancer; 2007 Apr; 120(8):1664-8. PubMed ID: 17230502
[TBL] [Abstract][Full Text] [Related]
17. Cell type-specific roles of histone deacetylase in TR ligand-independent transcriptional repression.
Lizcano F; Koibuchi N; Fukuda H; Dangond F; Chin WW
Mol Cell Endocrinol; 2001 Feb; 172(1-2):13-20. PubMed ID: 11165035
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 activation of ESX gene expression.
Neve RM; Ylstra B; Chang CH; Albertson DG; Benz CC
Oncogene; 2002 May; 21(24):3934-8. PubMed ID: 12032832
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.
Sowa Y; Orita T; Minamikawa S; Nakano K; Mizuno T; Nomura H; Sakai T
Biochem Biophys Res Commun; 1997 Dec; 241(1):142-50. PubMed ID: 9405248
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter.
Wang S; Zhu J
J Biol Chem; 2003 May; 278(21):18842-50. PubMed ID: 12611896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
